TRBV11-2: A Potential Drug Target (G28581)

Target Name: TRBV11-2

NCBI ID: G28581

TRBV11-2

Other Name(s): TCRBV11S2 | TCRBV21S3A2N2T | T cell receptor beta variable 11-2 | TRBV112

TRBV11-2: A Potential Drug Target

TRBV11-2 (TcRBV11S2) is a protein that is expressed in various tissues of the body, including the brain, heart, kidneys, and intestine. It is a member of the T-cell receptor family 11 (TCRBV) and is involved in the regulation of immune responses and inflammation.

TRBV11-2 has been identified as a potential drug target due to its unique structure and its involvement in several diseases, including cancer, autoimmune disorders, and neurodegenerative diseases.

One of the key features of TRBV11-2 is its extracellular domain, which consists of a N-terminal region that is rich in positively charged amino acids and a C-terminal region that is rich in negatively charged amino acids. This structure is similar to that of several other TCRBV proteins, including TRBV6 and TRBV8, and is thought to play a key role in the protein's functions.

TRBV11-2 has been shown to interact with several different proteins, including the adaptor protein PDZP2 and the co-factor protein Fc纬R1. These interactions may help to regulate the activity of TRBV11-2 and influence its function in various tissues.

In addition to its interactions with other proteins, TRBV11-2 has also been shown to play a role in the regulation of immune responses and inflammation. This is thought to be due to its involvement in the T-cell receptor signaling pathway, which is involved in the regulation of immune responses and is a key component of the immune system.

TRBV11-2 has also been shown to be involved in the regulation of cell survival and apoptosis. This is thought to be due to its involvement in the Bcl-2 protein, which is a negative regulator of cell survival and is involved in the regulation of cell apoptosis.

In conclusion, TRBV11-2 is a protein that has been shown to play a key role in the regulation of immune responses and inflammation. Its unique structure and its involvement in several diseases make it an attractive target for drug development. Further research is needed to fully understand the functions of TRBV11-2 and its potential as a drug.

Protein Name: T Cell Receptor Beta Variable 11-2

Functions: V region of the variable domain of T cell receptor (TR) beta chain that participates in the antigen recognition (PubMed:24600447). Alpha-beta T cell receptors are antigen specific receptors which are essential to the immune response and are present on the cell surface of T lymphocytes. Recognize peptide-major histocompatibility (MH) (pMH) complexes that are displayed by antigen presenting cells (APC), a prerequisite for efficient T cell adaptive immunity against pathogens (PubMed:25493333). Binding of alpha-beta TR to pMH complex initiates TR-CD3 clustering on the cell surface and intracellular activation of LCK that phosphorylates the ITAM motifs of CD3G, CD3D, CD3E and CD247 enabling the recruitment of ZAP70. In turn ZAP70 phosphorylates LAT, which recruits numerous signaling molecules to form the LAT signalosome. The LAT signalosome propagates signal branching to three major signaling pathways, the calcium, the mitogen-activated protein kinase (MAPK) kinase and the nuclear factor NF-kappa-B (NF-kB) pathways, leading to the mobilization of transcription factors that are critical for gene expression and essential for T cell growth and differentiation (PubMed:23524462). The T cell repertoire is generated in the thymus, by V-(D)-J rearrangement. This repertoire is then shaped by intrathymic selection events to generate a peripheral T cell pool of self-MH restricted, non-autoaggressive T cells. Post-thymic interaction of alpha-beta TR with the pMH complexes shapes TR structural and functional avidity (PubMed:15040585)

The "TRBV11-2 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about TRBV11-2 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets